Characterizing the Wnt Pathway in Advanced Prostate Cancer: When, Why, and How

Eur Urol. 2020 Jan;77(1):22-23. doi: 10.1016/j.eururo.2019.06.029. Epub 2019 Jul 9.

Authors

Sumanta K Pal¹, Umang Swami², Neeraj Agarwal³

Affiliations

¹ Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
² Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
³ Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Electronic address: [email protected].

PMID: 31300236
DOI: 10.1016/j.eururo.2019.06.029

No abstract available

Publication types

Editorial
Comment

MeSH terms

Androstenes
Benzamides
Humans
Male
Mutation
Nitriles
Phenylthiohydantoin / analogs & derivatives
Prostatic Neoplasms*
Prostatic Neoplasms, Castration-Resistant*
Wnt Signaling Pathway

Substances

Androstenes
Benzamides
Nitriles
Phenylthiohydantoin
enzalutamide
abiraterone